 |
|
Staging Workup, Sentinel Node Biopsy, and Follow-up Tests for Melanoma
Update of Current Concepts
Timothy M. Johnson, MD;
Carol R. Bradford, MD;
Stephen B. Gruber, MD, PhD;
Vernon K. Sondak, MD;
Jennifer L. Schwartz, MD
Arch Dermatol. 2004;140:107-113.
Objectives To clarify and update workup and follow-up strategies based on fundamental principles and current data, and to discuss new and current concepts regarding sentinel lymph node biopsy (SLNB), particularly in relation to the staging workup.
Data Sources Studies conducted from 1995 to 2003 were identified by PubMed search. Additional searches included workup for reference lists of retrieved articles when applicable, and PubMed-related articles.
Study Selection Contemporary studies with good design, conclusions based on sound methods, and results pertaining to staging workup, SLNB, and follow-up tests were critically reviewed.
Data Extraction Data and conclusions based on the above studies were incorporated into a review.
Data Synthesis Routine tests have marginal to no efficacy and are not cost-efficient for detecting occult disease in asymptomatic patients with localized melanoma. The only staging test that has relatively high sensitivity and specificity and provides tissue diagnosis is SLNB; moreover, SLNB has revolutionized our understanding of lymphatic pathways. The concepts of interval nodes and unexpected lymphatic drainage pathways have been addressed by several recent reports. There are no data that demonstrate any significant difference in overall survival for detection of asymptomatic vs symptomatic stage IV melanoma.
Conclusions An initial workup is useful for staging and prognosis to identify occult disease, with potential outcome benefit if treated early; and, by detecting distant occult disease (stage IV), to obviate the need for an extensive surgical procedure and thereby avoid associated increased morbidity. The foundation for the workup and follow-up remains thorough history taking and a physical examination, combined with a low index of suspicion for symptom-directed tests.
From the Departments of Dermatology (Drs Johnson and Schwartz), Otolaryngology (Drs Johnson and Bradford), Internal Medicine and Epidemiology (Dr Gruber), and Surgery (Drs Johnson and Sondak), University of Michigan Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor. The authors have no relevant financial interest in this article.
RELATED ARTICLES
Early Detection of Asymptomatic Pulmonary Melanoma Metastases by Routine Chest Radiographs Is Not Associated With Improved Survival
Hensin Tsao, Myra Feldman, Julie E. Fullerton, Arthur J. Sober, Daniel Rosenthal, and William Goggins
Arch Dermatol. 2004;140(1):67-70.
ABSTRACT
| FULL TEXT
Sentinel Node Biopsy for High-Risk Nonmelanoma Cutaneous Malignancy
Jeffrey D. Wagner, David Z. Evdokimow, Edward Weisberger, David Moore, Tsu-Yi Chuang, Stacie Wenck, and John J. Coleman, III
Arch Dermatol. 2004;140(1):75-79.
ABSTRACT
| FULL TEXT
Primary Dermal Melanoma: A Distinct Subtype of Melanoma
Susan M. Swetter, Phillip M. Ecker, Denise L. Johnson, and Jeff D. Harvell
Arch Dermatol. 2004;140(1):99-103.
ABSTRACT
| FULL TEXT
|
